After multivariate adjusting for baseline characteristics, there was a significant trend for an increased risk of all hyperkalemia and hypokalemia events with the increase of initial eGFR decline, specifically for those with an initial eGFR decline of 30% to 40%, 40% to 50%, and >50% following SGLT2i treatment (Figure S6 ).
← all excerpts
Initial eGFR Changes with SGLT2 Inhibitor in Patients With Type 2 Diabetes and Associations With the Risk of Abnormal Serum Potassium Level.
1
—
—